Psoriasis Clinical Trials in Chicago

Showing 161-180 of 198 trials

Evaluate the Effect of Elimune Capsules

NCT02251678

Elorac, Inc. is evaluating the effect of Elimune™ capsules on biomarkers C-reactive protein (CRP), Tumor Necrosis Factor (αTNF), Interleuken-2 (IL-2), Interleuken-6 (IL-6), Interleuken-12 (IL-12) in subjects with plaque psoriasis with or without arthritis. Psoriasis is a chronic inflammatory skin disease with polygenic predisposition combined with triggering factors such as trauma, inflammation or medication. Elimune™ is a uniquely formulated prescription dietary supplement for oral administration. Each capsule contains a proprietary blend of natural ingredients, Vitamin D3, Folic Acid, Nicotinamide, Eicosapentaenoic Acid, Doscosahexaenoic Acid, Quercetin, Curcumin, Glycyrrhizin, and Hesperetin, which share anti-inflammatory activities including the ability to inhibit tumor necrosis factor-α (TNF-α).

Plaque Psoriasis

Elorac, Inc.21 participantsStarted Sep 2014

Chicago, Illinois, United States • Lake Forest, Illinois, United States • Fair Lawn, New Jersey, United States +1 more locations

COMPLETED2.2 miles

A Study to Evaluate Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE)

NCT00096928

This was a multicenter, prospective, 5-year surveillance study of approximately 5000 Raptiva-treated patients and approximately 500 non-Raptiva treated patients (formerly 2500 comparison patients who were treated with a biologic therapy other than Raptiva) with chronic moderate to severe plaque psoriasis who were candidates for treatment with Raptiva.

Psoriasis

Genentech, Inc.1,846 participantsStarted Mar 2005

Birmingham, Alabama, United States • Daphne, Alabama, United States • Gadsden, Alabama, United States +179 more locations

Evaluate the Effect of Elimune Capsules

A Study to Evaluate Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE)

Psoriasis Trials in Other Cities

Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index

Long Term Study to Evaluate Safety and Efficacy of M518101 in Subjects With Plaque Psoriasis

Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens

Generic Tazarotene Cream, 0.05% for the Treatment of Plaque Psoriasis

An Exploratory Genetic Study in Participants With Psoriasis

Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis

Tofacitinib Ointment For Chronic Plaque Psoriasis

Study of the Efficacy of Cloderm® Cream in the Treatment of Moderate Plaque Psoriasis

Paired-Comparison Study Evaluating the Efficacy and Safety of E6201 Versus Vehicle for the Treatment of Plaque-Type Psoriasis

AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis

Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients

Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis One of Two Phase 3 Studies

A Study of BMS-582949 in Patients With Moderate to Severe Plaque Psoriasis

A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.

Study to Evaluate Effect of Pandel Cream 0.1% on HPA Axis in Pediatric and Adult Population

A Study of Multiple Doses of AbGn-168H by Intravenous Infusion in Patients With Moderate to Severe Chronic Plaque Psoriasis

T and B Cell Responses in Autoimmune Diseases

Study to Evaluate Apo805K1 in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Other Conditions in Chicago